DT5aP-IPV-Hib 5-component Pertussis vaccine

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

DiphtheriaHaemophilus Influenzae Type bHealthyInfantPertussisPoliomyelitisTetanus

Phase 3

Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

CompletedNCT00287092

Sanofi Pasteur, a Sanofi CompanyDiphtheria, Haemophilus Influenzae Type b, Pertussis +2

Start: 2006-02-28End: 2008-09-30Updated: 2015-01-07

Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®

CompletedNCT00355654

Sanofi Pasteur, a Sanofi CompanyHealthy, Infant

Start: 2006-09-30End: 2008-07-31Updated: 2015-01-07

Related Papers

Randomized, Controlled, Multicenter Study of the Immunogenicity and Safety of a Fully Liquid Combination Diphtheria–Tetanus Toxoid–Five-Component Acellular Pertussis (DTaP<sub>5</sub>), Inactivated Poliovirus (IPV), and Haemophilus influenzae Type b (Hib) Vaccine Compared with a DTaP<sub>3</sub>-IPV/Hib Vaccine Administered at 3, 5, and 12 Months of Age

Clinical and Vaccine Immunology2013-08-2110 citations

Safety and immunogenicity of fully liquid DTaP₅-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP₃-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: a phase III, modified double-blind, randomized, controlled, multicenter study.

2012-06-093 citations